Understanding patient preferences for risperidone dosage forms
A Study on the Preference of Risperidone Dosage Forms
Shanghai Mental Health Center · NCT06657430
This study is trying to understand what patients and their caregivers prefer when it comes to different forms of the antipsychotic medication risperidone, to help improve treatment satisfaction and adherence.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Shanghai Mental Health Center (other) |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06657430 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on gathering insights into patients' needs and preferences regarding different dosage forms of the antipsychotic medication risperidone. By evaluating the clinical value of patch-form antipsychotics, the study aims to enhance treatment adherence and patient satisfaction. Participants include individuals diagnosed with schizophrenia, bipolar disorder, autism spectrum disorder, or mental retardation, along with their primary caregivers. The study is conducted at the Shanghai Mental Health Center, where data will be collected to inform future treatment options.
Who should consider this trial
Good fit: Ideal candidates include patients with schizophrenia, bipolar disorder, autism spectrum disorder, or mental retardation, as well as their primary caregivers.
Not a fit: Patients who have difficulty reading and understanding Chinese or who refuse to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment adherence and satisfaction for patients using risperidone.
How similar studies have performed: While this approach is focused on patient preferences, similar studies have shown that understanding patient needs can lead to better treatment outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with schizophrenia, bipolar disorder, autism spectrum disorder, mental retardation or their primary caregivers who voluntarily participate in the study. Exclusion Criteria: * Have difficulty reading and understanding Chinese or refuse to participate in the study.
Where this trial is running
Shanghai, Shanghai Municipality
- Shanghai Mental Health Center — Shanghai, Shanghai Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Lan Luo, Doctor of Medicine
- Email: lan-luo@foxmail.com
- Phone: +8618516544150
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Schizophrenia, Bipolar Affective Disorder, Autism Spectrum Disorder, Conduct Disorder, Mental Retardation, risperidone, patch, cross-sectional study